Join to View Full Profile
3924 Sw 57th AvePortland, OR 97221
Phone+1 503-244-4280
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Nancy Slifman, MD is a dermatologist in Portland, Oregon. She is currently licensed to practice medicine in Oregon, Ohio, and Massachusetts.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Dermatology, 1988 - 1991
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Allergy and Immunology, 1985 - 1987
Mass General Brigham/Massachusetts General Hospital/Beth Israel Deaconess Medical Center/Brigham and Women's HospResidency, Dermatology, 1982 - 1984
Oregon Health & Science University (OHSU Health)Fellowship, Public Health and General Preventive Medicine, 1978 - 1980
University of Rochester Medical CenterResidency, Pediatrics, 1976 - 1977
University of Texas Southwestern Medical Center/Children's HealthInternship, Transitional Year, 1974 - 1975
Tufts University School of MedicineClass of 1974
Certifications & Licensure
OR State Medical License 1978 - 2025
MA State Medical License 1976 - 2015
OH State Medical License 1982 - 1982
American Board of Pediatrics Pediatrics
Publications & Presentations
PubMed
- 152 citationsLeukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.Niveditha Mohan, Evelyne T. Edwards, Thomas R. Cupps, Nancy R. Slifman, Jong-Hoon Lee
The Journal of Rheumatology. 2004-10-01 - 289 citationsListeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.Nancy R. Slifman, Sharon K. Gershon, Jong-Hoon Lee, Evelyne T. Edwards, M. Miles Braun
Arthritis and Rheumatism. 2003-02-01 - 334 citationsLife-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.Jong-Hoon Lee, Nancy R. Slifman, Sharon K. Gershon, Evelyne T. Edwards, William D. Schwieterman
Arthritis and Rheumatism. 2002-10-01
